세계 심혈관 기기 시장 규모는 2024년 623억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 1,013억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 5.5%를 보일 것으로 예측됩니다. 중재적 심장학 시술의 도입은 좋은 상환 정책과 함께 시장 성장을 가속하고 있습니다.
주요 시장 성장 촉진요인심부전, 관상동맥 질환, 부정맥 등 심혈관 질환 증가가 시장을 촉진하고 있습니다. 또한, 빠른 회복, 입원 기간 단축, 환자 편의성 향상 등을 위해 기존의 개심술을 대체할 수 있는 최소침습적 수술에 대한 소비자의 선호도가 높아지는 것도 또 다른 중요한 성장 촉진요인으로 작용하고 있습니다.
주요 시장 동향 : 3D 프린팅과 인공지능(AI) 기술의 발전으로 정밀도와 안전성이 강화된 첨단 심혈관 기기가 출시되고 있는 것은 시장 전체를 자극하는 새로운 트렌드 중 하나입니다.
지리적 동향 : 잘 정비된 의료 인프라가 북미 시장을 강화하고 있습니다. 이와는 별도로, 주요 의료기기 제조업체의 존재와 R&D 활동에 대한 투자 증가는 이 지역 시장에 더욱 긍정적인 영향을 미치고 있습니다.
경쟁 구도: 심혈관 기기 시장 개요에 따르면, 세계 시장에서 저명한 기업으로는 Abbott Laboratories,B. Braun Melsungen AG,Biotronik,Boston Scientific Corporation,Canon Medical Systems Corporation,Cardinal Health Inc.,Edwards Lifesciences Corporation,General Electric Company,LivaNova PLC,Medtronic PLC,Siemens Healthineers GmbH(Siemens AG), Terumo Cardiovascular Systems Corporation(Terumo Corporation) 등이 있습니다.
과제와 기회: 심혈관 기기 출시는 복잡한 엔지니어링과 첨단 재료의 통합을 수반하기 때문에 시장 성장에 걸림돌이 될 수 있습니다. 그러나 주요 기업들은 특히 이식형 장치의 장기적인 신뢰성과 안전성을 보장하기 위해 노력하고 있습니다. 이는 향후 몇 년 동안 세계 시장을 계속 확대할 것입니다.
최소침습 수술에 대한 수요
전통적인 개심술에서 회복 시간 단축, 수술 위험 감소, 환자 예후 개선 등을 실현하는 최소 침습적 수술로 개인 선호도가 변화하고 있는 것이 시장을 자극하고 있습니다. 예를 들어, 2024년 4월 골웨이 대학 연구팀이 감독한 FAST TRACK CABG 연구는 심장 우회 수술의 계획, 유도 및 수행에 대한 새로운 접근 방식을 처음으로 환자를 대상으로 검증했습니다. 이 연구는 AI를 활용한 혈류 스캔을 통한 비침습적 심장 CT가 실현 가능하고 안전하다는 것을 입증했습니다. 이 외에도 로봇 공학 및 실시간 영상 기술의 보급으로 큰 절개 없이도 판막이나 스텐트 등을 정확하게 배치할 수 있게 되면서 심혈관 기기 시장의 수익이 증가하고 있습니다. 예를 들어, 2024년 2월 Philips는 Fiber Optic RealShape(FORS) 기술을 탑재한 LumiGuide를 출시하여 방사선을 사용하지 않는 최소침습 수술을 실현했습니다. 이와는 별도로, 최소침습 수술은 특수 심혈관 기기와 첨단 영상 기술을 사용하여 작은 절개창을 통해 이루어지며, 이를 통해 표적화된 정밀한 치료가 가능합니다. 대표적인 예로는 경 카테터 승모판막 성형술(TMVR), 경 카테터 대동맥판막 치환술(TAVR), 내시경적 정맥채취술 등이 있습니다. 그 결과, 이러한 시술은 전 세계적으로 인기를 끌고 있습니다. 예를 들어, 2022년 12월 세계 헬스케어 기업 중 하나인 Abbott는 인도에서 수술 위험이 높거나 매우 높은 중증 대동맥판막 협착증 환자를 대상으로 새로운 경피적 대동맥판막 이식술(TAVI) 시스템인 나비톨(Navitol)의 출시를 발표했습니다. 기술의 발전에 따라 이러한 시술은 더욱 효과적이고 안전해졌으며, 그 결과 많은 심혈관계 질환의 치료에 채택되고 있습니다. 예를 들어, 2024년 5월 미국심혈관조영 및 중재시술학회(SCAI) 연례회의에서 발표된 새로운 1년간의 데이터에 따르면, Anteris Technologies가 개발한 새로운 생체모방 경피적 대동맥판막치환술(TAVR) 시스템은 중증 대동맥판막협착증(AS)을 치료할 수 있는 새로운 방법을 제시합니다. AS)를 치료할 수 있는 새로운 방법을 심장 전문의에게 제공할 수 있습니다.
강화된 변종 도입
심혈관 기기는 만성 심장질환과 뇌졸중의 치료, 진단 및 관리에 있어 중요한 역할을 하고 있습니다. 이에 따라 주요 기업들은 의료 전문가들이 심혈관 질환의 심각성을 정확하게 평가하고, 환자의 심장 건강 상태를 모니터링하며, 효과적인 치료법을 개선할 수 있는 새로운 기기를 출시하고 있습니다. 또한, 심혈관 질환을 치료하기 위해 중재를 필요로 하는 환자가 증가함에 따라 스마트 스텐트, 이식형 심박조율기, 제세동기 등의 인기가 높아지고 있습니다. 이는 심혈관 기기 시장 전망에 긍정적인 영향을 미치고 있습니다. 예를 들어, 2023년 12월 테르모 인도는 관상동맥 질환 치료를 위한 약물 용출형 스텐트 'Ultimaster Nagomi'의 출시를 발표했습니다. 이 외에도 심박조율기를 포함한 개량형 심혈관 기기 도입을 위한 연구개발 활동에 대한 투자가 확대되고 있는 것도 중요한 성장 촉진요인으로 작용하고 있습니다. 예를 들어, 2023년 5월, 심장 리듬 관리 분야의 세계적인 개발 기업 중 하나인 MicroPort사는 광범위한 이식형 심박조율기인 Alizea와 Celea에 대한 FDA 승인을 획득했습니다. 또한, MRI 검사를 받는 환자의 안전성을 높이기 위해 MicroPort가 개발한 알고리즘인 AutoMRI 모드를 탑재하고 있습니다. 마찬가지로 2023년 7월, 애보트사는 무독성 공간 제조업체 시스템인 아베일 DR의 FDA 승인을 발표하였습니다. 또한, 머신러닝과 AI는 치료 계획의 개인화, 환자 결과 예측, 진단 정확도 향상 등을 위해 방대한 심혈관 데이터 분석에 활용되고 있습니다. 예를 들어, 2024년 1월 미국 메이요 클리닉의 순환기 전문의 중 한 명인 Demilade Adedinsewo 박사가 이끄는 연구는 AI 기반 디지털 청진기가 임산부의 심근을 약화시켜 생명을 위협할 수 있는 질환인 주산기 심근증 진단을 개선할 수 있다는 가능성을 제시했습니다. 했습니다.
전략적 파트너십
저명한 기업, 의료기기 제조업체, 연구기관, 의료기관들은 정밀 영상 진단 도구를 포함한 심혈관 기기를 도입하기 위해 공동 연구 및 M&A 활동을 진행하고 있습니다. 이는 심혈관 기기 시장의 최근 비즈니스 기회 중 하나가 되고 있습니다. 예를 들어, 2023년 9월 심장 데이터 관리 플랫폼의 선두주자인 PaceMate사는 MedAxiom사와의 제휴를 발표하며 단일 클라우드 네이티브 환경에서 심장 데이터와 EHR 데이터 워크플로우 솔루션을 구축했습니다. 이에 따라 2023년 10월 GE헬스케어는 보스턴 사이언티픽(Boston Scientific)과 제휴하여 향상된 심장 영상 시스템을 개발했습니다. 또한, 이러한 제휴는 복잡한 규제 상황을 극복하고 국제 시장에 진출할 때 파트너의 현지 전문 지식과 확립된 판매망을 활용하여 기업을 지원할 수 있습니다. 예를 들어, 2023년 6월 Philips는 바이오트로닉(Biotronik)과 파트너십을 체결하여 Philips 심포니 스위트 고객이 사용할 수 있는 심혈관 기기의 범위를 확대했습니다. 이 외에도 2023년 5월 페이스메이트는 FDA 승인을 받은 개인용 심전도 기술 및 원격 환자 관리 솔루션의 세계 리더인 얼라이브코어(AliveCor)와 제휴하여 이식형 심장 장치를 포괄하는 파트너십을 맺었습니다.
The global cardiovascular devices market size reached USD 62.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 101.3 Billion by 2033, exhibiting a growth rate (CAGR) of 5.5% during 2025-2033. The introduction of interventional cardiology procedures, coupled with favorable reimbursement policies, are stimulating the market growth.
Major Market Drivers: The increasing number of cardiovascular conditions, such as heart failure, coronary artery disease, arrhythmias, etc., is propelling the market. Moreover, the rising consumer inclination towards minimally invasive alternatives to traditional open-heart surgeries for faster recovery, reduced hospital stays, improved patient comfort, etc., is also acting as another significant growth-inducing factor.
Key Market Trends: The growing advancements in 3D printing and artificial intelligence (AI) technologies that are leading to the launch of advanced cardiovascular devices to offer enhanced precision and safety are among the emerging trends stimulating the overall market.
Geographical Trends: The well-developed healthcare infrastructures are bolstering the market in North America. Apart from this, the presence of major medical device manufacturers and the elevating investments in R&D activities are further positively influencing the regional market.
Competitive Landscape: According to the cardiovascular devices market overview, some of the prominent companies across the global market include Abbott Laboratories, B. Braun Melsungen AG, Biotronik, Boston Scientific Corporation, Canon Medical Systems Corporation, Cardinal Health Inc., Edwards Lifesciences Corporation, General Electric Company, LivaNova PLC, Medtronic PLC, Siemens Healthineers GmbH (Siemens AG), and Terumo Cardiovascular Systems Corporation (Terumo Corporation), among many others.
Challenges and Opportunities: The launch of cardiovascular devices involves complex engineering and integration of advanced materials, which can hamper the market growth. However, key players are ensuring the long-term reliability and safety of these devices, particularly those that are implantable. This, in turn, will continue to augment the global market in the coming years.
Demand for Minimally Invasive Procedures
The shifting preferences of individuals from traditional open-heart surgeries toward less invasive methodologies that minimize recovery times, reduce surgical risks, improve patient outcomes, etc., are stimulating the market. For example, in April 2024, the FAST TRACK CABG study, overseen by a team of researchers at the University of Galway, tested a new approach to the planning, guidance, and conducting of heart bypass surgery on patients for the first time. It demonstrated that non-invasive cardiac CT with AI-powered blood flow scanning is feasible and safe. Besides this, the widespread adoption of robotics and real-time imaging techniques facilitates the accurate placement of valves, stents, and other devices without the need for large incisions, which is also elevating the cardiovascular devices market revenue. For instance, in February 2024, Philips introduced LumiGuide, which is powered by Fiber Optic RealShape (FORS) technology, for radiation-free, minimally invasive surgeries. Apart from this, minimally invasive procedures are performed via small incisions using specialized cardiovascular instruments and advanced imaging techniques, which allow for targeted and precise treatments. Some of the common examples include transcatheter mitral valve repair (TMVR), transcatheter aortic valve replacement (TAVR), endoscopic vein harvesting, etc. Consequently, they are gaining traction across the globe. For example, in December 2022, Abbott, one of the leading global healthcare companies, announced the launch of its novel transcatheter aortic valve implantation (TAVI) system, Navitor, for individuals in India with severe aortic stenosis who are at high or extreme surgical risk. As technology advances, these procedures are becoming more effective and safer, thereby leading to their increasing adoption in treating numerous cardiovascular conditions. For instance, in May 2024, according to new one-year data presented at the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI), a new biomimetic transcatheter aortic valve replacement (TAVR) system developed by Anteris Technologies can offer cardiologists with a new way to treat severe aortic stenosis (AS).
Introduction of Enhanced Variants
Cardiovascular devices play a crucial role in the treatment, diagnosis, and management of chronic heart conditions and stroke. Consequently, key players are launching novel devices that enable healthcare professionals to accurately assess the severity of cardiovascular diseases, monitor the heart health of patients, improve effective therapies, etc. Moreover, the increasing number of patients requiring intervention to address their cardiovascular conditions is escalating the popularity of smart stents, implantable pacemakers, defibrillators, etc. This, in turn, is positively influencing the cardiovascular devices market outlook. For example, in December 2023, Terumo India announced the launch of Ultimaster Nagomi, a drug-eluting stent intended for use in the treatment of coronary artery disease. Besides this, the growing investments in R&D activities to introduce improved cardiovascular devices, including pacemakers, are acting as significant growth-inducing factors. For instance, in May 2023, MicroPort, one of the global developers in the field of cardiac rhythm management, received FDA approval for its wide range of implantable pacemakers, Alizea and Celea. Additionally, they feature AutoMRI mode, an algorithm invented by MicroPort, that increases the safety of patients who are undergoing an MRI examination. Similarly, in July 2023, Abbott announced the FDA approval of its leadless pacemaker system, Aveir DR. Furthermore, machine learning and AI are employed for analyzing vast amounts of cardiovascular data to personalize treatment plans, predict patient outcomes, improve diagnostic accuracies, etc. For example, in January 2024, research led by Dr. Demilade Adedinsewo, one of the cardiologists at the Mayo Clinic in the U.S., suggested that the AI-enabled digital stethoscope could improve the diagnosis of peripartum cardiomyopathy, a potentially life-threatening condition that weakens the heart muscle of women during pregnancy.
Strategic Partnerships
Prominent companies, medical device manufacturers, research institutions, and healthcare organizations are collaborating and entering into mergers and acquisitions activities to introduce cardiovascular devices, including precise imaging tools. This represents one of the cardiovascular devices market recent opportunities. For instance, in September 2023, PaceMate, one of the leading cardiac data management platforms, announced the partnership with MedAxiom to create workflow solutions for cardiac and EHR data in a single, cloud-native environment. In line with this, in October 2023, GE HealthCare collaborated with Boston Scientific to develop enhanced cardiac imaging systems. Additionally, these partnerships aid companies in navigating complex regulatory landscapes and gaining access to international markets by leveraging the local expertise and established distribution networks of their partners. For example, in June 2023, Philips entered into a partnership with Biotronik to expand the range of cardiovascular devices available for Philips SymphonySuite customers. Besides this, in May 2023, PaceMate collaborated with AliveCor, one of the global leaders in FDA-cleared personal electrocardiogram technology and remote patient management solutions, to encompass implantable cardiac devices.
Therapeutic and surgical devices is the most popular device type
The increasing number of surgical procedures and therapeutic interventions aimed at treating cardiovascular diseases is propelling the segment's growth. Moreover, therapeutic and surgical devices include implantable cardioverter defibrillators (ICDs), stents, pacemakers, catheters, heart valves, ventricular assist devices (VADs), etc. They aid in regulating heart rhythm, restoring blood flow, providing mechanical circulatory support, etc. Consequently, they are gaining extensive traction as less invasive alternatives to traditional open-heart surgeries, which is elevating the cardiovascular devices market demand. For example, in December 2023, Medtronic plc, one of the global leaders in healthcare technologies, announced the FDA approval of the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). In line with this, in June 2023, Magenta Medical launched a feasibility study for the world's smallest heart pump that reduces vascular access complications during heart surgery.
Coronary artery disease (CAD) dominates the cardiovascular devices market share
CAD devices used for treatment, diagnosis, and management of coronary artery disease condition are gaining traction across countries. Moreover, the widespread adoption of diagnostic devices, such as intravascular ultrasound (IVUS) devices, angiography systems, and computed tomography angiography (CTA) machines, as they help in assessing the severity of coronary artery blockages, is propelling the market. For example, in August 2022, Medtronic announced the launch of its novel drug-eluting coronary stent, the Onyx Frontier drug-eluting stent (DES), following CE Mark approval. Besides this, in January 2024, Cleerly, one of the companies working to create a new standard of care for the diagnosis of heart disease, introduced Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance. Cleerly ISCHEMIA analysis software is an automated machine learning-based decision support tool specifically designed for patients undergoing coronary computed tomography angiography (CCTA).
Hospitals account for the majority of the overall market share
Hospitals are the primary end users of cardiovascular devices. They provide a wide range of cardiac services, such as treatment, diagnosis, and surgical procedures for cardiovascular diseases. Hospitals have cardiac catheterization labs and specialized cardiology departments equipped with advanced imaging systems and surgical suites, which is increasing the cardiovascular devices market's recent price. For instance, in January 2024, Sylvia Jones, the health minister of Ontario, announced the development of a new cardiac lab at St. Mary's General Hospital in Kitchener, Canada, to help cardiac patients. They require a comprehensive range of devices, such as implantable devices, diagnostic equipment, surgical instruments, monitoring systems, etc., which is driving the growth in this segmentation.
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest market for cardiovascular devices.
The increasing prevalence of cardiovascular conditions, including stroke and peripheral artery disease, is propelling the regional market. For instance, as per the report published by the Heart and Stroke Foundation of Canada in February 2022, there were 750,000 patients diagnosed with heart failure. Moreover, favorable reimbursement policies and fast regulatory approvals are acting as significant growth-inducing factors. For example, in September 2023, CorVista Health announced the FDA approval of its non-invasive medical device system that is used for detecting the presence of cardiac disease. In line with this, in January 2024, Occlutech, a Swedish medical device company focused on structural heart disease, received the U.S. FDA approval for its ASD Occluder for the treatment of atrial septal defects (ASDs). Apart from this, as per the cardiovascular devices market statistics, the introduction of wireless ECG has allowed for real-time patient monitoring and diagnosis. This, in turn, will continue to stimulate the regional market in the coming years. For example, in February 2021, VivaLNK developed a wearable ECG monitoring solution designed to wirelessly capture ECG and heart rate during a six-minute walk test (6MWT).
The key players are investing significantly in R&D to develop innovative cardiovascular devices. They focus on improving device performance, durability, and patient outcomes. R&D efforts aim to introduce advanced technologies, such as minimally invasive procedures, remote monitoring systems, and personalized medicine approaches. Additionally, cardiovascular devices market companies are continuously launching new cardiovascular devices to expand their product portfolios. These launches often involve next-generation devices with improved features and enhanced capabilities. They are prioritizing addressing unmet clinical needs, such as novel therapies for specific cardiovascular conditions or devices that offer improved precision and ease of use. Besides this, collaborations and partnerships between key players, healthcare providers, and research institutions are common in the cardiovascular devices market. These collaborations foster innovation, facilitate knowledge exchange, and leverage collective expertise and resources to develop and commercialize new technologies and solutions.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include: